AC Immune S.A. (ACIU) tiene un P/E histórico negativo de -3.8, lo que significa que la empresa actualmente no es rentable en base a los últimos doce meses (TTM). El P/E futuro de 6.3 basado en estimaciones de analistas sugiere que se espera un retorno a la rentabilidad. El rendimiento de ganancias histórico es -26.34%, rendimiento de ganancias futuro 15.85%.
Criterios demostrados por esta página:
Puntuación General SharesGrow: 52/100 con 2/7 criterios aprobados.
| Year | P/E (TTM) | Ratio PEG | Ratio P/B | Ratio P/S | Rendimiento por Dividendo |
|---|---|---|---|---|---|
| 2016 | -93.2 | 0.68 | 4.65 | 28.50 | - |
| 2017 | -28.1 | -0.12 | 6.35 | 36.64 | - |
| 2018 | -11.3 | -0.14 | 3.24 | 79.92 | - |
| 2019 | 12.8 | -0.07 | 2.14 | 5.27 | - |
| 2020 | -5.3 | 0.02 | 1.53 | 21.33 | - |
| 2021 | -4.6 | -0.36 | 1.46 | 0.00 | - |
| 2022 | -2.2 | 0.18 | 0.93 | 40.03 | - |
| 2023 | -6.6 | 0.27 | 2.22 | 24.06 | - |
| 2024 | -4.8 | 0.24 | 2.18 | 8.95 | - |
| 2025 | -3.7 | -0.12 | 5.58 | 70.23 | - |
| Year | EPS (Diluido) | Ingresos | Ingreso Neto | Margen Neto |
|---|---|---|---|---|
| 2016 | $-0.14 | $23.21M | $-7.1M | -30.6% |
| 2017 | $-0.46 | $20.26M | $-26.41M | -130.4% |
| 2018 | $-0.82 | $7.19M | $-50.95M | -708.2% |
| 2019 | $0.64 | $111.03M | $45.44M | 40.9% |
| 2020 | $-0.86 | $15.43M | $-62.11M | -402.5% |
| 2021 | $-0.97 | $0.00 | $-73M | - |
| 2022 | $-0.85 | $3.94M | $-70.75M | -1798% |
| 2023 | $-0.64 | $14.8M | $-54.23M | -366.4% |
| 2024 | $-0.51 | $27.31M | $-50.92M | -186.4% |
| 2025 | $-0.67 | $3.57M | $-67.28M | -1883% |
| Year | EPS (Prom.) | Rango EPS | Ingresos (Prom.) | Rango de Ingresos | Analistas |
|---|---|---|---|---|---|
| 2026 | $-0.34 | $-0.43 – $-0.25 | $28.18M | $9.86M – $46.48M | 2 |
| 2027 | $0.50 | $0.08 – $0.92 | $131.34M | $87.02M – $175.65M | 2 |
| 2028 | $0.22 | $-1.12 – $1.06 | $998.04K | $610.95K – $1.59M | 3 |
| 2029 | $0.40 | $0.20 – $0.71 | $998.04K | $610.95K – $1.59M | 1 |
| 2030 | $0.39 | $0.19 – $0.68 | $2M | $1.22M – $3.17M | 1 |
